NCI, EPA Attempt to Resolve Differences Over Childhood Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

BETHESDA, Md--Officials of the National Cancer Institute (NCI) and the Environmental Protection Agency (EPA) are attempting to resolve their conflicting interpretations of data regarding cancer in children. The NCI has forcefully challenged the EPA’s contention that the United States is in the midst of an epidemic of childhood malignancies.

BETHESDA, Md--Officials of the National Cancer Institute (NCI) and the Environmental Protection Agency (EPA) are attempting to resolve their conflicting interpretations of data regarding cancer in children. The NCI has forcefully challenged the EPA’s contention that the United States is in the midst of an epidemic of childhood malignancies.

An EPA conference last September declared that cancer in US children has increased steadily over the last quarter century and that the situation demands a focused program to determine the cause of the increase and find means of prevention. This led to a reassessment by NCI epidemiologists of data from the Institute’s Surveillance, Epidemiology, and End Results (SEER) program.

Martha Linet, MD, who led the NCI review, said that her group found "no evidence of a consistent increase in the incidence during 1973 to 1994 for specific types of childhood cancer."

In late January, senior EPA and NCI officials met for more than 2 hours to discuss the childhood cancer data, Hugh W. McKinnon, MD, of EPA’s National Risk Management Research Laboratory in Cincinnati, reported at the NCAB February meeting. They agreed that staff scientists from the two agencies would hold further meetings to try to resolve the conflicting interpretation of the childhood cancer statistics.

"Honest scientists will have honest disagreements over data, and we are trying to understand that data," Dr. McKinnon told Oncology News International.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Treatment-related toxicities during neuro-oncology therapy appear well managed with dose modifications and treatment cycle holds.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content